Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GNMK's Cash to Debt is ranked higher than
99% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. GNMK: No Debt )
GNMK' s 10-Year Cash to Debt Range
Min: 8.53   Max: No Debt
Current: No Debt

Equity to Asset 0.89
GNMK's Equity to Asset is ranked higher than
95% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. GNMK: 0.89 )
GNMK' s 10-Year Equity to Asset Range
Min: 0.67   Max: 0.92
Current: 0.89

0.67
0.92
F-Score: 4
Z-Score: 19.33
M-Score: -3.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -127.28
GNMK's Operating margin (%) is ranked lower than
53% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. GNMK: -127.28 )
GNMK' s 10-Year Operating margin (%) Range
Min: -4488.56   Max: -106.95
Current: -127.28

-4488.56
-106.95
Net-margin (%) -122.77
GNMK's Net-margin (%) is ranked lower than
52% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. GNMK: -122.77 )
GNMK' s 10-Year Net-margin (%) Range
Min: -4383.77   Max: -107.98
Current: -122.77

-4383.77
-107.98
ROE (%) -30.82
GNMK's ROE (%) is ranked higher than
54% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. GNMK: -30.82 )
GNMK' s 10-Year ROE (%) Range
Min: -285.43   Max: -30.82
Current: -30.82

-285.43
-30.82
ROA (%) -27.63
GNMK's ROA (%) is ranked higher than
51% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. GNMK: -27.63 )
GNMK' s 10-Year ROA (%) Range
Min: -186.91   Max: -27.63
Current: -27.63

-186.91
-27.63
ROC (Joel Greenblatt) (%) -406.01
GNMK's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. GNMK: -406.01 )
GNMK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1478.87   Max: -309.46
Current: -406.01

-1478.87
-309.46
Revenue Growth (%) 44.20
GNMK's Revenue Growth (%) is ranked higher than
98% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. GNMK: 44.20 )
GNMK' s 10-Year Revenue Growth (%) Range
Min: -22.3   Max: 52.5
Current: 44.2

-22.3
52.5
EBITDA Growth (%) -20.80
GNMK's EBITDA Growth (%) is ranked higher than
59% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. GNMK: -20.80 )
GNMK' s 10-Year EBITDA Growth (%) Range
Min: -63.4   Max: -20.8
Current: -20.8

-63.4
-20.8
EPS Growth (%) -20.30
GNMK's EPS Growth (%) is ranked higher than
61% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. GNMK: -20.30 )
GNMK' s 10-Year EPS Growth (%) Range
Min: -62.8   Max: -20.3
Current: -20.3

-62.8
-20.3
» GNMK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

GNMK Guru Trades in Q3 2012

Jim Simons 31,600 sh (New)
» More
Q4 2012

GNMK Guru Trades in Q4 2012

Jim Simons 46,160 sh (+46.08%)
» More
Q1 2013

GNMK Guru Trades in Q1 2013

Jim Simons 72,400 sh (+56.85%)
» More
Q2 2013

GNMK Guru Trades in Q2 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GNMK



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.60
GNMK's P/B is ranked higher than
62% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. GNMK: 4.60 )
GNMK' s 10-Year P/B Range
Min: 1.61   Max: 10.43
Current: 4.6

1.61
10.43
P/S 17.09
GNMK's P/S is ranked higher than
52% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. GNMK: 17.09 )
GNMK' s 10-Year P/S Range
Min: 9.44   Max: 24.96
Current: 17.09

9.44
24.96
EV-to-EBIT -9.11
GNMK's EV-to-EBIT is ranked higher than
57% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. GNMK: -9.11 )
GNMK' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -9.11

Current Ratio 10.15
GNMK's Current Ratio is ranked higher than
95% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. GNMK: 10.15 )
GNMK' s 10-Year Current Ratio Range
Min: 3.19   Max: 14.02
Current: 10.15

3.19
14.02
Quick Ratio 9.98
GNMK's Quick Ratio is ranked higher than
96% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. GNMK: 9.98 )
GNMK' s 10-Year Quick Ratio Range
Min: 3.15   Max: 13.78
Current: 9.98

3.15
13.78

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.40
GNMK's Price/Net Cash is ranked higher than
96% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GNMK: 5.40 )
GNMK' s 10-Year Price/Net Cash Range
Min: 1.98   Max: 13.27
Current: 5.4

1.98
13.27
Price/Net Current Asset Value 5.20
GNMK's Price/Net Current Asset Value is ranked higher than
94% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GNMK: 5.20 )
GNMK' s 10-Year Price/Net Current Asset Value Range
Min: 1.91   Max: 11.04
Current: 5.2

1.91
11.04
Price/Tangible Book 4.50
GNMK's Price/Tangible Book is ranked higher than
72% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 6.18 vs. GNMK: 4.50 )
GNMK' s 10-Year Price/Tangible Book Range
Min: 1.64   Max: 8.28
Current: 4.5

1.64
8.28
Price/Median PS Value 1.10
GNMK's Price/Median PS Value is ranked higher than
73% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. GNMK: 1.10 )
GNMK' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 1.54
Current: 1.1

0.63
1.54

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:GNF.Germany
GenMark Diagnostics, Inc., was incorporated in the State of Delaware in February 2010. The Company is a molecular diagnostics company developing and commercializing its proprietary eSensor detection technology. Its proprietary electrochemical technology enables fast, accurate and highly sensitive detection of up to 72 distinct biomarkers in a single sample. The Company's XT-8 System received 510(k) clearance from the Food and Drug Administration and is designed to support molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified nucleic acid sample, its XT-8 system produces clear results. The Company's XT-8 System supports up to 24 test cartridges, of which each could be run independently, resulting in a highly convenient and flexible workflow for its customers, which are hospitals and reference laboratories. It intends to expand the use of its XT-8 System and diagnostic tests to those reference laboratories and hospitals in the United States which perform a high volume of molecular diagnostic tests. The Company's XT-8 System is an automated molecular diagnostic system that enables reference laboratories and hospitals to perform fast, accurate and easy-to-use molecular diagnostic tests. The XT-8 System, which employs its proprietary electrochemical detection technology, consists of a compact bench-top workstation with an integrated touch screen computer and an analyzer into which the self-contained, disposable test cartridges are inserted. The Company's proprietary eSensor technology is based on the competitive DNA hybridization and electrochemical detection. The Company's test cartridges are self-contained devices specifically programmed and configured for a given diagnostic test. Each test cartridge includes a sample compartment and a plastic cover that forms a hybridization chamber. The Company's XT-8 instrument is a multiplex workstation that has a modular design consisting of a base module and up to three test cartridge-processing towers of eight cartridge slots each. It faces competition in the molecular diagnostic testing markets with testing products and systems developed by public and private companies such as Cepheid, Gen-Probe, Inc., Siemens, Hologic, Inc., Innogenetics, Inc, Luminex Corporation, Nanosphere, Inc., Qiagen NV, Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd., Idaho Technologies and Abbott Diagnostics, a division of Abbott Laboratories. The Company's diagnostic tests also face competition with the LDTs developed by national and regional reference laboratories and hospitals. The design, development, manufacture, testing and sale of its diagnostic products are subject to regulation by numerous governmental authorities, the FDA, and corresponding state and foreign regulatory agencies.
» More Articles for GNMK

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: XPL, GNMK Jul 02 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
GenMark Diagnostics Schedules Second Quarter 2014 Financial Results Conference Call for August 11,... Jul 17 2014
GenMark Diagnostics to Present at the William Blair 2014 Growth Stock Conference Jun 06 2014
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 04 2014
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 29 2014
GenMark management meetings positive, says William Blair May 28 2014
GenMark Diagnostics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) May 15 2014
GENMARK DIAGNOSTICS, INC. Financials May 14 2014
GenMark appoints Scott Mendel as CFO May 12 2014
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... May 12 2014
GenMark Diagnostics Appoints Scott Mendel Chief Financial Officer May 12 2014
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 06 2014
GenMark Diagnostics Reports First Quarter 2014 Results May 06 2014
Q1 2014 GENMARK DIAGNOSTICS INC Earnings Release - After Market Close May 06 2014
GenMark Diagnostics Schedules First Quarter 2014 Financial Results Conference Call for May 6, 2014 Apr 24 2014
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 12 2014
GenMark Diagnostics Management Discusses Q4 2013 Results - Earnings Call Transcript Mar 11 2014
GenMark Diagnostics Reports Fourth Quarter and Year End 2013 Results Mar 11 2014
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 11 2014
GenMark Diagnostics Reports Fourth Quarter and Year End 2013 Results Mar 11 2014
GenMark Diagnostics Schedules Fourth Quarter and Year-End 2013 Financial Results Conference Call for... Feb 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide